Indian Journal of Medical and Paediatric Oncology
Referenz
Pujade-Lauraine E, Ledermann JA, Selle F. et al; SOLO2/ENGOT-Ov21 investigators.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
[published correction appears in Lancet Oncol. 2017 Sep;18(9):e510]
Lancet Oncol 2017;
18 (09) 1274-1284
Pujade-Lauraine E, Ledermann JA, Selle F. et al; SOLO2/ENGOT-Ov21 investigators.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
[published correction appears in Lancet Oncol. 2017 Sep;18(9):e510]
Lancet Oncol 2017;
18 (09) 1274-1284
Bibliographische Angaben herunterladen
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.